West Pharmaceutical Services, Inc.
$274.81
▲
0.03%
2026-04-22 10:12:13
www.westpharma.com
NYQ: WST
Explore West Pharmaceutical Services, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.81 B
Current Price
$274.81
52W High / Low
$322.34 / $193.05
Stock P/E
40.51
Book Value
$44.11
Dividend Yield
0.33%
ROCE
17.6%
ROE
16.86%
Face Value
—
EPS
$6.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,800
Beta
1.15
Debt / Equity
10.27
Current Ratio
3.02
Quick Ratio
2.34
Forward P/E
28.94
Price / Sales
6.02
Enterprise Value
$18.01 B
EV / EBITDA
22.23
EV / Revenue
5.86
Rating
Buy
Target Price
$316.69
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Meaningful dividend yield is available.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Retractable Technologies, Inc. | $0.65 | — | $19.46 M | 1.18% | -10.73% | -15.56% | $1.14 / $0.62 | $2.48 |
| 2. | Milestone Scientific Inc. | $0.29 | — | $23.33 M | — | -155% | -1.32% | $1.11 / $0.22 | $0.04 |
| 3. | Cuprina Holdings (Cayman) Limited | $0.33 | — | $2.47 M | — | 34.48% | -1.39% | $9.5 / $0.28 | $0.28 |
| 4. | Bionano Genomics, Inc. | $1.31 | — | $14.53 M | — | -65.83% | -66.15% | $5.5 / $1.06 | $4.14 |
| 5. | NEXGEL, Inc. | $0.64 | — | $6.98 M | — | -41.75% | -52.74% | $2.99 / $0.56 | $0.64 |
| 6. | Lucyd, Inc | $1.07 | — | $6.68 M | — | -93.41% | -83.6% | $4.97 / $0.95 | $1.65 |
| 7. | Solventum Corporation | $69.51 | 7.83 | $12.08 B | — | 5.66% | 38.86% | $88.2 / $62.38 | $29.1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 805 M | 804.6 M | 766.5 M | 698 M | 748.8 M | — |
| Operating Profit | 175.1 M | 174.5 M | 158.9 M | 127.6 M | 169.8 M | — |
| Net Profit | 132.1 M | 140 M | 131.8 M | 89.8 M | 130.1 M | — |
| EPS in Rs | 1.83 | 1.94 | 1.83 | 1.25 | 1.8 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.07 B | 2.89 B | 2.95 B | 2.89 B |
| Operating Profit | 636.1 M | 590.9 M | 707.4 M | 760.8 M |
| Net Profit | 493.7 M | 492.7 M | 593.4 M | 585.9 M |
| EPS in Rs | 6.85 | 6.84 | 8.23 | 8.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.27 B | 3.64 B | 3.83 B | 3.62 B |
| Total Liabilities | 1.09 B | 961.1 M | 948.5 M | 931.9 M |
| Equity | 3.18 B | 2.68 B | 2.88 B | 2.68 B |
| Current Assets | 1.98 B | 1.54 B | 1.94 B | 1.92 B |
| Current Liabilities | 654.9 M | 550.4 M | 671.8 M | 519 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 754.8 M | 653.4 M | 776.5 M | 724 M |
| Investing CF | -285.9 M | -378.7 M | -368.7 M | -288.2 M |
| Financing CF | -185.1 M | -622.6 M | -459.6 M | -293.6 M |
| Free CF | 468.9 M | 276.4 M | 414.5 M | 439.4 M |
| Capex | -285.9 M | -377 M | -362 M | -284.6 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.92% | 2.18% | — | — |
| Earnings Growth % | -16.97% | 1.28% | — | — |
| Profit Margin % | 17.03% | 20.12% | 20.3% | — |
| Operating Margin % | 20.42% | 23.98% | 26.35% | — |
| Gross Margin % | 34.51% | 38.28% | 39.36% | — |
| EBITDA Margin % | 25.71% | 28.62% | 28% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-01-28 | $0.22 |
| 2025-11-12 | $0.22 |
| 2025-07-30 | $0.21 |
| 2025-04-30 | $0.21 |
| 2025-02-07 | $0.21 |
Stock Splits
No stock split history available.